Clinical Trials in North Carolina

Showing 7801-7820 of 20,428 trials

A Study of Mirikizumab in Participants With Plaque Psoriasis

NCT03718884

This study is known as a "drug interaction study." The purpose is to learn how commonly used drugs or substances (midazolam, warfarin, dextromethorphan, omeprazole, and caffeine) and their breakdown products get into the bloodstream after taking a "cocktail" (combination) of them before and after multiple doses of mirikizumab. The study will last about 23 weeks for each participant. Screening must be completed within 4 weeks prior to study start.

Psoriasis

Eli Lilly and Company29 participantsStarted Oct 2018

Anaheim, California, United States • DeLand, Florida, United States • High Point, North Carolina, United States

TERMINATEDPhase 1/246 miles

Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)

NCT02152956

Open-label, multi-dose, single-arm, multi-center, Phase 1/2 study conducted in three segments: the Single Patient Dose Escalation Segment (complete), followed by the Multi-Patient Dose Escalation Segment (complete) and the Maximum Tolerated Dose and Schedule (MTDS) Expansion Cohort Segment (closed). Having characterized safety and determined the maximum tolerated dose and schedule, the primary objective of this study now is to assess the anti-neoplastic activity of flotetuzumab in patients with PIF/ER AML, as determined by the proportion of patients who achieve CR or CRh. Starting with Cycle 2, patients who are benefiting from flotetuzumab may receive up to a maximum of 8 cycles of treatment. Patients will receive daily increasing doses of flotetuzumab for the first week of Cycle 1 (Lead-In Dosing) followed by 3 weeks of continuous intravenous infusion at a the assigned dose. Subsequent cycles are each 4 weeks of continuous infusion at the assigned dose. Dosing may continue for up to 8 cycles. Follow up visits may continue for 6 months after treatment is discontinued.

AML

MacroGenics244 participantsStarted Jun 2014

Duarte, California, United States • La Jolla, California, United States • San Francisco, California, United States +40 more locations

A Study of Mirikizumab in Participants With Plaque Psoriasis

Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)

Find Trials by Condition in North Carolina

Study to Evaluate the Iovera° Device for Temporary Relief From Knee Pain

Study to Evaluate the Effect of FX006 on Synovial Inflammation in Patients With OA of the Knee

Study to Evaluate the Efficacy and Safety of FX006 in Patients With Glenohumeral Osteoarthritis or Shoulder Adhesive Capsulitis

V160 2-Dose and 3-Dose Regimens in Healthy Cytomegalovirus (CMV) Seronegative Females (V160-002)

Study of FX006 for the Treatment of Pain in Patients With Osteoarthritis of the Knee

CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL

EPI-743 for Mitochondrial Respiratory Chain Diseases

Study to Evaluate the Efficacy and Safety of FX006 in Patients With Hip Osteoarthritis

Incorporating Supersaturated Oxygen in Shock

Study of FX006 vs Normal Saline in Patients With Osteoarthritis of the Knee

A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors

A Study to Assess Long-Term Safety of the CyPass Micro-Stent in Patients Completing the COMPASS Trial

A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia

A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers

Study to Compare Exposure of TA Following Administration of FX006 or TAcs in Patients With OA of the Shoulder or Hip

Study to Compare Exposure of TA Following Administration of Either FX006 or TAcs in Patients With Bilateral Knee OA

Study to Evaluate a Procedure for Intra-articular Injection of FX006 in Patients With Osteoarthritis of the Hip

A Study to Evaluate the Safety and Tolerability of Tirbanibulin Ointment 1% in Adult Participants With Actinic Keratosis